Observation study of clinical efficacy of Bevacizumab combined with Chemotherapy for advanced and metastatic Cancer
10.3760/cma.j.issn.1008-6315.2012.12.006
- VernacularTitle:贝伐单抗联合化疗治疗晚期转移性恶性肿瘤的临床效果观察
- Author:
Chunrong ZHU
;
Dapeng LI
;
Feng XIONG
;
Yanbo ZHU
;
Ledong SONG
;
Qingcai WANG
- Publication Type:Journal Article
- Keywords:
Bevacizumab;
Cancer;
Chemotherapy
- From:
Clinical Medicine of China
2012;28(12):1249-1252
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the therapeutic efficacy and toxicity of Bevacizumab combined with Chemotherapy in patients with advanced and metastatic cancer.Methods Fifty-nine patients of advanced metastatic cancer (Forty-two patients of refractory metastatic colorectal cancer and 17 advanced adenocarcinoma) were treated with normalized chemotherapy combined with Bevacizumab.Patients with refractory metastatic colorectal cancer were treated with Bevacizumab combined with FOLFIRI or FOLFOX4,and patients with advanced adenocarcinoma of NSCLC were treated with Bevacizumab in combination with docetaxel and cisplatin for 4-6 cycles,Bevacizumab was used until progressive disease (PD).During treatment,adverse effect were assessed with Common Toxicity Criteria V3.0 developed by National Cancer Institute.Results Among the 42 patients of metastatic colorectal cancer,27 were treated with First-line 1 with complete remission (CR),13 partial response(PR),4 stable disease(SD) and 9 PD,the effective rate (ER) was 51.9％ ( 5/15 ),disease control rate(DCR) was 66.7％ (18/27);Fifteen patients were treated with second-line PR,of which 5 PRD,4 SD,6 PD.ER was 33.3％ (5/15),and DCR was 60.0％ (9/15).The effective rate were slightly higher in the First-line treatment group than that in the second-line treatment group,however,the difference was not statistically significant (x2=1.335,P=0.248 ).Among the 17 patients of NSCLC,of which 1 CR,7 PR,5 SD,4 PD.RR was 47.1％ (8/17),and DCR was 76.5％ (13/17).The major toxicities were one grade 3 hemoptysis observed in one patient,grade 3 thrombosis was observed in one patient.Other common adverse effects,were epistaxis,hemoptysis,hypertension and proteinuria,which were not severe and could be well tolerated.Conclusion Bevacizumab Combined with Chemotherapy was effective in short term for the patients with advanced and metastatic cancerMost patients could tolerate the side effects.Further studies should be done to prove the long-term effects.
